With €55 billion invested in R&D in Europe in 2024, the pharmaceutical industry is the sector that invests the greatest percentage of its revenue in R&D. However, Europe is facing increasing competition from emerging economies: rapid growth in the market and research environments in countries such as China are contributing to the move of economic and research activities to non-European markets. In 2024 China outpaced both US and Europe as originators of new active substances launched for the first time on the world market. After having lost its crown as the top innovation region in the world in 2000, Europe is now on the third place on the podium as originator of new molecules.

Read the full report here.

Collaboration between the pharmaceutical industry, healthcare professionals, and patient organisations is fundamental to advancing healthcare and delivering better outcomes for patients. Bringing greater transparency to this already well-regulated and essential relationship builds public understanding and supports long-term collaboration.

That’s why, ten years ago, EFPIA members began disclosing payments to healthcare professionals and organisations.

Learn more here.